Osteoporosis is endemic in the US and other Western societies and fractures are a serious medical problem among aging Veterans and their peers in the general population with 1 in 2 females and 1 in 4 males over the age of 50 projected to suffer an osteoporosis related bone fracture in their lifetimes. Fractures lead to huge healthcare expenditures, loss of mobility and significant morbidity. Hip fractures almost always require major surgery and mortality rates are extremely high in aged individuals following surgery, approaching 24% in the general population and reaching as high as 32% in male veterans. Historically, anti-resorptive drugs (such as bisphosphonates) have been the mainstay of anti-osteoporosis therapy/fracture prevention and although these agents stall further bone degeneration and lead to an increase in bone mineral density, they are inefficient at restoring high quality, remodelled bone and many patients treated with these drugs ultimately still go on to sustain a fracture. Compliance in taking anti-resorptive agents is furthermore extremely poor with multiple large population studies conducted in major healthcare systems all reporting abysmal patient compliance with typically 75% of patients discontinuing their anti-resorptive medications within a year of initiation, due to inconvenient administration schedules, side-effects and costs. Recently, rare but potentially serious complications of long term anti-resorptive use have led to hysteria among the public and an unprecedented and alarming retreat from pharmacological fracture prevention therapy is now underway. This has led to a call for action by the ASBMR leadership, however clearly, other pharmacological alternatives are now even more urgently needed. In contrast to anti-catabolic agents, drugs based on parathyroid hormone (PTH) such as Teriparatide (PTH (1-34)) and Preotact (PTH (1-84)), are the only FDA approved bone anabolic therapies capable of stimulating bone formation and reversing bone loss, thus reducing the odds of fracture. Although additional bone anabolic drugs are in development, potential side-effects have indefinitely delayed final FDA approval of Amgen?s anti-sclerostin antibody Romosozumab. PTH-based anabolics, like Teriparatide, are thus likely to remain the only available bone anabolic agents for the near future. Teriparatide however, has significant limitations of its own that have constrained its wider application, including inconvenient daily injection and rapidly waning efficacy. During the tenure of this Merit program we made the unexpected discovery that the pharmacological T cell immunosuppressant Abatacept (CTLA4-Ig), used in the therapy of inflammatory diseases, such as rheumatoid arthritis, mediates a bone anabolic signal. When Abatacept renders T cells dormant (anergic), it transforms them into Wnt10b secreting cells. Wnt10b is a ligand for the Wnt-signal transduction pathway, that promotes bone formation by stimulating differentiation and activity of osteoblasts. Teriparatide itself promotes bone formation in part by upregulating Wnt10b in T cells. We hypothesized, and demonstrated, that by priming T cells to undergo anergy, Abatacept is able to amplify the anabolic activity of Teriparatide in mice. As Abatacept alone has more modest bone anabolic activity than Teriparatide alone, our Merit renewal proposes to investigate methods to intensify the bone anabolic activity of Abatacept, Teriparatide and Abatacept and Teriparatide together.
In Aim 1 we will investigate whether raising basal T cell activation state can amplify the bone anabolic activities of Abatacept and Teriparatide, alone and in combination, by enhancing the capacity of T cells to secrete enhanced concentrations of Wnt10b in response to these stimuli.
In Aim 2 we will examine if Abatacept and/or Teriparatide enhance bone anabolic activity in the context of an inflammatory environment such as rheumatoid arthritis, using the collagen induced arthritis mouse model. Because T cell anergy is dependent on sustained cAMP signalling and the Wnt10b gene promoter is regulated in part through cAMP response elements (CREs), Aim 3 will examine the role of cAMP signalling in T cells and Wnt10b generation by anergic T cells.

Public Health Relevance

Fractures are a serious medical problem among aging Veterans and in the general population with almost 50% of older women and 30% of older men likely to suffer a fracture in their lifetimes. Fractures can be devastating and are associated with crippling disability requiring rehabilitation in up to 75% of individuals with loss of independence and significant decline in quality of life. A 2007 study of elderly veterans by Bass et al., reported that mortality within one year of hip fracture was 18% for women and 32% for men. Economic burden of fracture in the US is projected to reach $25 billion/annum by 2025. As the largest integrated health care system in the US, the VA is on the front lines of fracture treatment and rehabilitation and will have to continue to wrestle with these ever-expanding medical costs. The studies in this application deal with novel mechanisms to promote bone regeneration using pharmacological manipulation to exploit a recently identified quirk in the immune system, capable of promoting new bone formation. Our goal is to improve bone density to prevent fracture.

Agency
National Institute of Health (NIH)
Institute
Veterans Affairs (VA)
Type
Non-HHS Research Projects (I01)
Project #
2I01BX000105-09
Application #
9563531
Study Section
Endocrinology B (ENDB)
Project Start
2009-04-01
Project End
2022-09-30
Budget Start
2018-10-01
Budget End
2019-09-30
Support Year
9
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Veterans Health Administration
Department
Type
DUNS #
824835805
City
Decatur
State
GA
Country
United States
Zip Code
30033
Weitzmann, M Neale (2017) Bone and the Immune System. Toxicol Pathol 45:911-924
Neale Weitzmann, M; Pacifici, Roberto (2017) Parathyroid Diseases and T Cells. Curr Osteoporos Rep 15:135-141
Li, Jau-Yi; Chassaing, Benoit; Tyagi, Abdul Malik et al. (2016) Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics. J Clin Invest 126:2049-63
Moran, Caitlin A; Weitzmann, M Neale; Ofotokun, Ighovwerha (2016) The protease inhibitors and HIV-associated bone loss. Curr Opin HIV AIDS 11:333-42
Ofotokun, Ighovwerha; Titanji, Kehmia; Lahiri, Cecile D et al. (2016) A Single-dose Zoledronic Acid Infusion Prevents Antiretroviral Therapy-induced Bone Loss in Treatment-naive HIV-infected Patients: A Phase IIb Trial. Clin Infect Dis 63:663-671
Weitzmann, M Neale; Ofotokun, Ighovwerha; Titanji, Kehmia et al. (2016) Bone Loss Among Women Living With HIV. Curr HIV/AIDS Rep 13:367-373
Li, Jau-Yi; D'Amelio, Patrizia; Robinson, Jerid et al. (2015) IL-17A Is Increased in Humans with Primary Hyperparathyroidism and Mediates PTH-Induced Bone Loss in Mice. Cell Metab 22:799-810
Ofotokun, Ighovwerha; Titanji, Kehmia; Vikulina, Tatyana et al. (2015) Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss. Nat Commun 6:8282
Weitzmann, M Neale; Ha, Shin-Woo; Vikulina, Tatyana et al. (2015) Bioactive silica nanoparticles reverse age-associated bone loss in mice. Nanomedicine 11:959-967
Ha, Shin-Woo; Weitzmann, M Neale; Beck Jr, George R (2014) Bioactive silica nanoparticles promote osteoblast differentiation through stimulation of autophagy and direct association with LC3 and p62. ACS Nano 8:5898-910

Showing the most recent 10 out of 13 publications